Pharmacokinetics and Safety of Imeglimin in Japanese Patients With Impaired Renal Function

Imeglimin is a diabetic drug excreted mainly in the urine; therefore, the impact of renal impairment on its pharmacokinetics (PK) is of interest. We assessed the PK and safety of imeglimin in Japanese patients with impaired renal function. This was an uncontrolled, open‐label, single‐dose, phase 1 study. Participants were classified into 4 groups by their estimated glomerular filtration rate (mL/min/1.73 m2) as follows: ≥90, normal renal function; and 60 to